The predominant assay (n=21) was based on the inhibition of TNF-α induced cytotoxicity of either murine fibroblast, L929 (47), or fibrosarcoma, WEHI-164 or the WEHI-13 variant cell-lines (48) followed by the reporter-gene assay (n=7) in which adalimumab inhibited TNF-stimulated activation of NF-κB transcription factor, assessed by measuring luciferase or secreted embryonic alkaline phosphatase (SEAP) activity in the human embryonic kidney cell-line, HEK-293 transfected with appropriate TNF-α responsive NFκB regulated reporter-gene constructs. This evidence concerns the gene TNF and fibrosarcoma.